MAZE THERAPEUTICS, INC. (MAZE) Debt Components
- 2026-06-30: Long-term Debt, Current MaturitiesUSD $0.00; Long-term Debt, Excluding Current MaturitiesUSD $38.96M; Long-term DebtUSD $38.96M; Long-Term Debt, Maturity, Year OneUSD $0.00.
- 2026-03-31: Long-term Debt, Current MaturitiesUSD $0.00; Long-term Debt, Excluding Current MaturitiesUSD $38.83M; Long-term DebtUSD $38.83M; Long-Term Debt, Maturity, Year OneUSD $0.00.
- 2025-09-30: Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m).
- 2025-06-30: Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m).
MAZE THERAPEUTICS, INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Current Maturities USD | Long-term Debt, Excluding Current Maturities USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Line of Credit Facility, Interest Rate During Period pure | Long-term Debt, Gross USD | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $38.96M | $38.96M | $0.00 | $0.00 | $0.00 | $33.60M | $6.40M | $0.00 | (m) | $40.00M | $-3.62M |
| 2026-03-31 | $0.00 | $38.83M | $38.83M | $0.00 | $0.00 | $0.00 | $33.60M | $6.40M | $0.00 | (m) | $40.00M | $-3.75M |
| 2025-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 9 month · 4.50% | (m) | (m) |
| 2025-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 6 month · 4.50% | (m) | (m) |
| 2025-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 1 month · 4.50% | (m) | (m) |
| 2025-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · 4.50% | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |